Ask AI
ProCE Banner Events

Redefining the Treatment of Squamous Cell Carcinoma of the Anal Canal (SCAC) | ZYNYZ® (retifanlimab-dlwr) The First and Only FDA-Approved PD-1 Inhibitor for Adults with Inoperable Locally Recurrent or Metastatic SCAC

Key Takeaways:

  • Describe the ZYNYZ indications and NCCN Guidelines recommendation
  • Review Squamous Cell Carcinoma of the Anal Canal (SCAC); including epidemiology, incidence, and risk factors
  • Review the clinical efficacy and safety data from the POD1UM-303 trial, including progression free survival (PFS), overall survival (ORR), and the safety profile for ZYNYZ
Time and location

Wednesday, July 02, 2025

12:15 PM - 12:45 PM Eastern Time (ET)

Virtual

Acknowledgement

Sponsored By

Incyte